Clinical-stage biopharmaceutical company developing therapies for cancer.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering treatments for various cancers within the United States. The company's robust pipeline features several promising clinical stage product candidates, including ORIC-533, an orally bioavailable small molecule inhibitor targeting CD73. This candidate aims to address resistance issues associated with chemotherapy and immunotherapy treatment regimens. ORIC-944, another key candidate, is an allosteric inhibitor of the polycomb repressive complex 2, specifically tailored for prostate cancer. Additionally, ORIC-114, a brain-penetrant orally bioavailable irreversible inhibitor, is designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating potent activity against exon 20 insertion mutations.
ORIC Pharmaceuticals is actively advancing multiple discovery-stage precision medicines that target various mechanisms of cancer resistance. The company has strategically positioned itself through collaborations, including a license and collaboration agreement with Voronoi Inc., and a significant license agreement with Mirati Therapeutics, Inc., further enhancing its innovative capabilities and potential treatment portfolio.
Founded in 2014 and headquartered in South San Francisco, California, ORIC Pharmaceuticals continues to leverage its deep expertise in oncology to push the boundaries of cancer therapy. The company remains dedicated to developing novel therapies that address unmet medical needs and improve outcomes for cancer patients worldwide.